|
|
Clinical
Trials
The
"Billy Foundation" is pleased to partner with the
following companies to bring to you the latest clinical trials
to aid in the education and fight against melanoma.
Current clinical trials are shown below.
Click here for the Billy Foundation Clinical Trial Match
Service!
Study to
compare investigational compound with existing therapies for
advanced melanoma
Clinical trial currently enrolling patients
A research study is underway
at 45 sites in the United States and up to 60 sites globally
to compare how long patients with advanced melanoma live
when they get the investigational compound to how long
patients live when they get either dacarbazine or
temozolomide, two of the available drug treatment options.
This Phase III study, known as A3671009, is seeking adults
(18 years of age and older) with surgically incurable Stage
IIIC or
IV melanoma
who have received no prior chemotherapy, immunotherapy, or
biologic therapy for the treatment of metastatic melanoma.
The investigational
compound, ticilimubab, is a fully human monoclonal antibody.
It is being studied to determine if it can stimulate
patients’ immune systems to attack their tumors.
For more information or to
determine your eligibility for participation in the study,
go to www.pfizeroncology.com to complete a patient
profile and talk to a study representative, or call
1-877-369-9753.
April 2008 -
Clinical Cancer Research
Lupeol Inhibits Growth of Highly Aggressive Human Metastatic Melanoma Cells
In vitro and In vivo by Inducing Apoptosis
You
can use this site to find a wealth of information about clinical
research, including listings of more than 41,000 active industry
and government-sponsored clinical trials, as well as new drug
therapies in research and those recently approved by the FDA.
Our site is designed to be an open resource for patients
interested in participating in clinical trials and for research
professionals.
Proleukin (IL-2) is FDA
approved for the treatment of Metastatic Melanoma.
For a partial list of physicians and institutions
experienced in the administration of Proleukin therapy,
please visit
www.proleukin.com/referral
Clinical
Trials at the Arizona Cancer Center
Provided
courtesy of Dr.
Evan Hersh
1. Canvaxin as adjuvant therapy for Stage III and IV
melanoma
2. Short term high dose adjuvant Interferon alpha
for Stage II and III melana
3. Protocols for Stage IV melanoma
b. DTIC with or without genasense
c. MDX0-010 (anti-CTLA-4 Ig) with or without DTIC
d. allovectin 7 intratumoral gene therapy
f. ABI 007 (taxol in an albumin nano particle) Phase I,
Phase II pending
g. ILX 651 Phase I (dolostatin analogue) Phase I, Phase
II pending |
Stanford
University Medical Center Clinical Trials for
Melanoma - Susan Swetter, MD
Stanford
is an active participant in the Eastern Cooperative
Oncology Group (ECOG) multicenter clinical
trials for melanoma, and a number of ECOG/Intergroup
studies are open for patients with high risk cutaneous
disease, regional nodal metastasis, and disseminated
disease.
Stanford ECOG Melanoma Protocols
1. E1602: A Randomized Phase II Trial of Multi-epitope
Vaccination with Melanoma Peptides for Cytotoxic T-Cells
and Helper T-Cells for Patients with Metastatic Melanoma
Purpose: To determine the cytotoxic T cell (CTL) response
to each of 12 melanoma peptides in vaccinated patients
with or without helper peptides. To estimate the rates
of clinical response and survival, in patients vaccinated
with a multi-peptide vaccine vaccine consisting of epitopes
for CTL alone, epitopes for T-helper cells alone, or
both.
Open to metastatic melanoma including mucosal, ocular
and unknown primary. Patients must be HLA A1, A2, or
A3 positive. Select patients with brain metastasis may
be included. Requires two undissected extremity nodal
basins
2. E2603: A Double-blind, Randomized, Placebo-Controlled
Phase III Trial of Carboplatin, Paclitaxel and Sorafenib
(BAY 43-9006) versus Carboplatin, Paclitaxel and Placebo
in Patients with Unresectable Locally Advanced or Stage
IV Melanoma
Purpose: This randomized, phase III trial is studying
chemotherapeutic agents (carboplatin and paclitaxel)
alone and in combination with sorafenib (a targeted
B-RAF inhibitor), to assess response in patients with
unresectable stage III or IV melanoma
This is a trial for newly diagnosed patients or patients
who have never received chemotherapy and includes mucosal
or unknown primary melanoma patients. Patients
with ocular melanoma or brain metastasis are excluded.
3. E1697:
A Phase III Randomized Study of Four Weeks High-Dose
Interferon Alfa-2b in Stage T2-T4 or N1 (Microscopic)
Melanoma
For newly diagnosed Stage IB (> 1.5 mm), Stage IIA-C,
Stage IIIA melanoma
4. E4697:
A Randomized Placebo-Controlled Phase III Trial of
Yeast Derived GM-CSF Vs Peptide Vaccination Vs GM-CSF
Plus Peptide Vaccination Vs Placebo in Patients with
‘No Evidence of Disease’ after Complete Surgical Resection
of ‘Locally Advanced’ and/or Stage IV Melanoma
Patients must also be HLA-A2 positive. Trial also includes
ocular and mucosal melanoma.
|
Clinical
Trials at The Angeles Clinic and Research Institute
Provided
courtesy of Dr.
Steven Oday
1. A Phase II Trial of
AmplimexonTM (imexon,inj.) Plus Dacarbazine (DTIC) in
chemotherapy Naïve Patients with Unresectable Stage
III or Stage IV Malignant Melanoma
2.
Randomized, Double-Blind, Placebo-Controlled Phase II
Study Comparing the Safety of MDX-010 Administered with
or Without Prophylactic Oral Budesonide (Entocort EC)
in Patients with Unresectable Stage III or IV Malignant
Melanoma
3.
A Multi-Center, Single Arm Phase II Study of MDX-010
(BMS-734016) Monotherapy in Patients with Previously
Treated Unresectable Stage III or IV Melanoma
4.
A Randomized, Double-Blind, Multi-Center, Phase II Fixed
Dose Study of Multiple Doses of Ipilimumab (MDX-010)
Monotherapy in Patients with Previously Treated Unresectable
Stage III or IV Melanoma
5.
A Multi-Center, Open Label, Phase II Study of Ipilimumab
(MDX-010) Extended-Treatment Monotherapy or Follow Up
for Patients Previously Enrolled in Ipilimumab (MDX-010)
Protocols
6.
A Phase II, Multi-Center, Blinded, Randomized, Controlled
Study of the Safety and Efficacy of the Human Monoclonal
Antibody to Humana? Integrins (CNTO95), alone and in
Combination with Dacarbazine, in Subjects with Stage
IV Melanoma
7.
A Randomized, Double-Blind, Multicenter Study Comparing
MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma
Peptide Vaccine, and Melanoma Peptide Vaccine Monotherapy
in HLA-A*0201-Positive Patients with Previously Treated
Unresectable Stage III or IV Melanoma REGIMEN (double-blind):
MDX-010 alone,MDX-010+Vaccine, Vaccine alone
8. Phase II Multicenter
study of induction Biochemotherapy concurrent Biochemotherapy
followed by Prophylactic Cranial Irradiation/ Temozolomide
and Maintenance Biotherapy in Responding Patients with
Metastatic Melanoma
|
|
